TCGA-LL-A8F5-01A-11R-A36F-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 20
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- HYPOXIA+0.420
- MYC_TARGETS_V2+0.410
- ALLOGRAFT_REJECTION+0.360
- INTERFERON_GAMMA_RESPONSE+0.360
- INTERFERON_ALPHA_RESPONSE+0.350
- GLYCOLYSIS+0.320
- IL6_JAK_STAT3_SIGNALING+0.290
- UV_RESPONSE_UP+0.280
- KRAS_SIGNALING_DN+0.270
Top 10 suppressed
- PROTEIN_SECRETION-0.390
- ESTROGEN_RESPONSE_EARLY-0.340
- UV_RESPONSE_DN-0.340
- MITOTIC_SPINDLE-0.330
- TGF_BETA_SIGNALING-0.300
- ANDROGEN_RESPONSE-0.170
- XENOBIOTIC_METABOLISM-0.140
- BILE_ACID_METABOLISM-0.130
- HEME_METABOLISM-0.110
- NOTCH_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A5S0-01A-11R-A28M-07 | — | E | 0.873 |
| 2 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.856 |
| 3 | TCGA-AO-A129-01A-21R-A10J-07 | — | E | 0.811 |
| 4 | TCGA-A7-A6VY-01A-12R-A33J-07 | — | E | 0.808 |
| 5 | TCGA-XF-A9T5-01A-11R-A42T-07 | — | — | 0.793 |
| 6 | TCGA-BH-A0RX-01A-21R-A084-07 | — | D | 0.790 |
| 7 | 20060013.TNBC | — | E | 0.786 |
| 8 | TCGA-GM-A2DF-01A-11R-A180-07 | — | E | 0.782 |
| 9 | TCGA-22-5471-01A-01R-1635-07 | — | cohortSQ2 | 0.782 |
| 10 | TCGA-BH-A0B3-01A-11R-A056-07 | — | E | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |